Surgery Partners Faces Shareholder Investigation Over $23.50 Per Share Merger with Bon Secours Mercy Health

What happened

Surgery Partners announced on October 26, 2026, that Bon Secours Mercy Health will acquire the company for $23.50 per share in a going-private transaction. Bain Capital, the largest stockholder, is rolling over its equity into the post-merger entity, aligning its interests with the buyer rather than taking cash. On November 3, 2026, law firm Bleichmar Fonti & Auld announced an investigation into the merger, signaling potential concerns about deal fairness or conflicts of interest for minority shareholders. The investigation does not yet allege wrongdoing, but it introduces uncertainty around the transaction's completion timeline and terms. The $23.50 offer represents a premium to the stock's February 2026 price of $15.50, but it remains below the prior base-case intrinsic value of $21 and bull-case $26 from the earlier DeepValue report, suggesting the board may have accepted a value that does not fully compensate for the company's long-term recovery potential.

Implication

Short-term, the stock will likely trade close to the offer price, with the investigation creating headline risk but not necessarily derailing a well-capitalized buyer. The key risk is deal termination or renegotiation if the investigation uncovers material conflicts, but such outcomes are uncommon for transactions with a significant shareholder rollover. For current holders, the rational stance is to evaluate whether to accept the deal price or seek appraisal rights only if they believe intrinsic value exceeds $23.50, but the prior DeepValue analysis suggests a base case of $21 and a bull case of $26, making the offer reasonably attractive. Longer term, if the merger fails, Surgery Partners would revert to its standalone operating challenges: commercial payer mix pressure, high leverage (net debt/EBITDA 6.85), and de novo execution risk, which previously priced the stock at $15.50. Therefore, investors should weigh the certainty of $23.50 against the low-probability upside of a higher standalone value, and monitor the investigation and any competing bids or shareholder opposition.

Thesis delta

The previous WAIT thesis rested on operational recovery and deleveraging, with a base case value of $21. The announced go-private transaction at $23.50 crystallizes value for shareholders but shifts the investment case to merger arbitrage, focusing on deal certainty and fairness. Given the offer exceeds my prior base case but falls short of the bull case, I would cautiously accept the premium but remain alert to investigation outcomes that could alter terms.